NCT01554631View on ClinicalTrials.gov

A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Acarbose (Glucobay ODT, BAYG5421)

DRUG

Acarbose (Glucobay, BAYG5421)

Trial Locations (1)

41061

Mönchengladbach

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01554631 - A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg | Biotech Hunter | Biotech Hunter